Compare BOOM & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOOM | SGMT |
|---|---|---|
| Founded | 1965 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8M | 169.4M |
| IPO Year | 1995 | 2021 |
| Metric | BOOM | SGMT |
|---|---|---|
| Price | $6.16 | $7.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $8.50 | ★ $26.13 |
| AVG Volume (30 Days) | 451.8K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $609,840,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.69 | $4.50 |
| 52 Week High | $9.20 | $11.41 |
| Indicator | BOOM | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 41.02 | 58.68 |
| Support Level | $6.08 | $7.09 |
| Resistance Level | $6.35 | $8.80 |
| Average True Range (ATR) | 0.40 | 0.39 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 34.59 | 71.05 |
DMC Global Inc operates a diversified family of technical product and process businesses serving the energy, industrial and infrastructure markets. Its business is organized into three segments: Arcadia, DynaEnergetics, and NobelClad. Arcadia Products supplies architectural building products, including exterior and interior framing systems, windows, urtain walls, storefronts etc to the commercial construction market. NobelClad is involved in the production of explosion-welded clad metal plates for use in the construction of corrosion-resistant industrial processing equipment and specialized transition joints. DynaEnergetics driver, designs manufactures and distributes products utilized by the oil and gas industry principally for the perforation of oil and gas wells.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.